nettem Kursanstieg. Hab ich mir wieder auf die WL gesetzt.
Gruss E.
chart.bigcharts.com/bc3/quickchart/...16&mocktick=1&rand=7881"
CURIS Issued U.S. Patent Covering Cancer Drug Candidates
WEDNESDAY, APRIL 09, 2003 8:13 AM
- BusinessWire
CAMBRIDGE, Mass., Apr 9, 2003 (BUSINESS WIRE) -- CURIS, Inc. (CRIS) - The U.S. Patent and Trademark Office yesterday issued a patent covering a class of compounds that are being developed by CURIS for use as cancer treatments.
These compounds have been specifically designed as inhibitors of a biological signaling pathway controlled by a protein called Hedgehog.
"Abnormal activation of the Hedgehog signaling pathway has been implicated in several cancers, including basal cell carcinoma, medulloblastoma, small cell lung cancer, and others," stated Dr. Lee Rubin, CURIS' Chief Scientific Officer. "We believe that inhibition of the Hedgehog pathway may prove to be a novel and significant addition to the therapeutic options available for the treatment of certain cancers."
U.S. Patent 6,545,005, entitled "Mediators of the Hedgehog Signaling Pathway, Compositions and Uses Related Thereto," encompasses one of several classes of small molecule antagonists of the Hedgehog pathway that are being developed by CURIS as cancer treatments. The Company is also evaluating antibody therapy as another means of blocking the Hedgehog signaling pathway.
"This patent is another in a series of composition and method patents that further provide broad intellectual property coverage to CURIS' Hedgehog pathway inhibition technologies," said Daniel Passeri, CURIS' President and Chief Executive Officer. "The potential utility of this approach for cancer treatment was well illustrated with a recent publication in The Proceedings of the National Academy of Sciences. In that report, one of CURIS' Hedgehog pathway antagonists, CUR-61414, demonstrated success in selectively killing cancer cells in two different models of basal cell carcinoma, a skin cancer with more than one million new cases diagnosed annually in the U.S."
About CURIS, Inc.
CURIS, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. CURIS' product development involves the use of proteins or small molecules to modulate these pathways. CURIS has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, and alopecia (hair loss). For more information, please visit the CURIS web site at www.curis.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release.
CURIS, Inc., Cambridge
Christopher U. Missling, Ph.D., 617/503-6587
or Marc F. Charette, Ph.D., 617/503-6629
(c) 2003 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
Gruss E.
CURIS Issued U.S. Patent Covering Cancer Drug Candidates
WEDNESDAY, APRIL 09, 2003 8:13 AM
- BusinessWire
CAMBRIDGE, Mass., Apr 9, 2003 (BUSINESS WIRE) -- CURIS, Inc. (CRIS) - The U.S. Patent and Trademark Office yesterday issued a patent covering a class of compounds that are being developed by CURIS for use as cancer treatments.
These compounds have been specifically designed as inhibitors of a biological signaling pathway controlled by a protein called Hedgehog.
"Abnormal activation of the Hedgehog signaling pathway has been implicated in several cancers, including basal cell carcinoma, medulloblastoma, small cell lung cancer, and others," stated Dr. Lee Rubin, CURIS' Chief Scientific Officer. "We believe that inhibition of the Hedgehog pathway may prove to be a novel and significant addition to the therapeutic options available for the treatment of certain cancers."
U.S. Patent 6,545,005, entitled "Mediators of the Hedgehog Signaling Pathway, Compositions and Uses Related Thereto," encompasses one of several classes of small molecule antagonists of the Hedgehog pathway that are being developed by CURIS as cancer treatments. The Company is also evaluating antibody therapy as another means of blocking the Hedgehog signaling pathway.
"This patent is another in a series of composition and method patents that further provide broad intellectual property coverage to CURIS' Hedgehog pathway inhibition technologies," said Daniel Passeri, CURIS' President and Chief Executive Officer. "The potential utility of this approach for cancer treatment was well illustrated with a recent publication in The Proceedings of the National Academy of Sciences. In that report, one of CURIS' Hedgehog pathway antagonists, CUR-61414, demonstrated success in selectively killing cancer cells in two different models of basal cell carcinoma, a skin cancer with more than one million new cases diagnosed annually in the U.S."
About CURIS, Inc.
CURIS, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. CURIS' product development involves the use of proteins or small molecules to modulate these pathways. CURIS has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, and alopecia (hair loss). For more information, please visit the CURIS web site at www.curis.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release.
CURIS, Inc., Cambridge
Christopher U. Missling, Ph.D., 617/503-6587
or Marc F. Charette, Ph.D., 617/503-6629
(c) 2003 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
